Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Peyronie's Disease (PD) Ability to read, write, and understand English 2. Age greater than or equal to 18 3. Age less than or equal to 70 4. Identification of acquired penile curvature of greater than 30 degrees and less than 90 degrees associated with palpable penile plaque on physical examination at screening 5. Screening total testosterone of less than 350 ng/dL, twice withine 30 days of treatment 6. Screening free testosterone of less than 1.5ng/dL (analog assay) or 100pg/mL (calculated) 7. Planning to initiate Xiaflex® injections at MHB 8. Willingness to initiate testosterone therapy 9. Willing to be followed at MHB for the next 3 months 10. Willing to provide informed consent for this study  Prior history of treatment for PD that includes surgery 2. Prior treatment with oral therapy for PD unless at least stopped 2 weeks prior to signing the informed consent (e.g. Potaba, Vitamin E, colchicines) 3. Previous exposure to exogenous T, clomiphene citrate, or other Selective Estrogen Receptor Modulators, unless off therapy for at least 12 weeks 4. Presence of dense calcified plaque by ultrasound at screening 5. Hypersensitivity to testosterone, stearic acid, or polyvinylpyrolidone (the constituents of Aveed®) 6. Unwillingness to start testosterone therapy 7. Screening total testosterone of greater than 350 ng/dL 8. Screening free testosterone of more than 1.5ng/dL (analog assay) or 100pg/mL (calculated) 9. Unable to achieve adequate erection with penile injection to assess degree of curvature 10. Prior history of definitive treatment for prostate cancer, bladder cancer, or other pelvic malignancies including surgery, external beam radiation therapy, brachytherapy, cryotherapy 11. Prior history of prostate cancer, hematologic disorders, chronic liver disease including cirrhosis and hepatitis C, disorders affecting the immune system, including infection with human immunodeficiency virus, or psychiatric disorders including major depression, schizophrenia, bipolar disease 12. Prior history of cerebrovascular accident, history of deep venous thrombosis within the past 5 years or history of untreated or severe sleep apnea 13. Screening PSA more than 4.0 ng/mL, unless prostate cancer has been excluded to the Investigator's satisfaction 14. Incapable of giving informed consent or complying with the protocol